Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3279 - Role of glutamine for preventing oxaliplatin induced peripheral neuropathy (GELUPO): results of randomized open-label phase II trial


08 Oct 2016


Poster Display


Ozan Yazici


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


O. Yazici1, A.P. Titiz2, N. Ozdemir1, S. Aksoy3, M.A. Sendur4, B. Arlı2, N. Zengin1

Author affiliations

  • 1 Medical Oncology, Ankara Numune Education and Research Hospital, 06100 - Ankara/TR
  • 2 Neurology, Ankara Numune Education and Research Hospital, 06100 - Ankara/TR
  • 3 Department Of Medical Oncology, Hacettepe University Faculty of Medicine, 06100 - Ankara/TR
  • 4 Department Of Medical Oncology, Yıldırım Beyazıt University, Faculty of Medicine, 06800 - Ankara/TR


Abstract 3279


Aimed to evaluate role of oral glutamine replacement for preventing neuropathy in patients with colorectal cancer receiving oxaliplatin.


The patients planned to receive modified FOLFOX6 were blindly 1:1 randomized to glutamine and control group. In both groups, prior to first mFOLFOX6 regimen and after 8 cycles of therapy detailed neurological examination and EMG was performed.Assuming a neuropathy rate was > 30 % and 10 % in control and glutamine and it was estimated a total of 80 patients needed to be randomized to achieve 80% statistical power with a p level of 0.05 and a 10% drop-out rate. The patients with neuropathy in basal EMG, diabetes, history of neuropathy were excluded. In glutamine group all of the patients received 3x10 gr/day glutamine given before and during chemotherapy until the control EMG. The secondary end point of study was quality of life evaluated by EORTC-QLQ C3O.


In between December 2013 and September 2015, eighty eligible patients were randomized glutamine (n = 40) and control (n = 40) group. In glutamine and control group basal and control EMG was performed in 87.5% (n = 35) and %80 (n = 32) of the patients, respectively. In between glutamine and control group after 8 cycles of therapy motor axonal and demyelinating neuropathy was detected in 8.5 % (n = 3) vs 18.7 % (n = 6) and 14.2 % (n = 5) vs 15.6 %(n = 5) of the patients and difference was not significant. In between glutamine and control group sensory axonal and demyelinating neuropathy was determined in 14.2 % (n = 5) vs 15.6 % (n = 5) and 17.1 % (n = 6) vs 18.7 % (n = 6) of patients, respectively (p = 1 and p = 0.8). Following the 8 cycles of therapy in control EMG there was no difference in between upper extremity and lower extremity distal latency, compound muscle action potential, motor nerve conduction velocity, F latency, compound nerve action potential and sensory nerve conduction velocity. The hematological and non-hematological toxicities were similar in between two groups. Basal and control median EORTC-QLQ scores were not different in between two groups (p = 0.46).


In final analysis of the current open label randomized phase II trial, oral glutamine replacement therapy was ineffective to prevent oxaliplatin induced neuropathy.

Clinical trial identification

ClinicalTrials.gov Identifier: NCT02024191

Legal entity responsible for the study

Ankara Numune Education and Research Hospital


Ankara Numune Education and Research Hospital


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings